Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation

被引:22
|
作者
Balci, Kevser Gulcihan [1 ]
Balci, Mustafa Mucahit [1 ]
Canpolat, Ugur [1 ]
Sen, Fatih [1 ]
Akboga, Mehmet K. [1 ]
Suleymanoglu, Muhammed [1 ]
Kuyumcu, Serdar [1 ]
Maden, Orhan [1 ]
Selcuk, Hatice [1 ]
Selcuk, Mehmet Timur [1 ]
机构
[1] Turkiye Yuksek Ihtisas Res & Educ Hosp, Dept Cardiol, Ankara, Turkey
关键词
atrial fibrillation; warfarin; apixaban; dabigatran; quality of life; anxiety; HOSPITAL ANXIETY; DEPRESSION; GUIDELINES; MANAGEMENT; VALIDITY; THERAPY; DISEASE; IMPACT;
D O I
10.5152/AnatolJCardiol.2015.6334
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to compare health-related quality of life (HRQoL) measures between novel oral anticoagulants (NOACs) and warfarin-treated Turkish patients who had been started on oral anticoagulants (OACs) due to non-valvular atrial fibrillation (AF) and to determine the effects of OACs on patient's emotional status, anxiety and depression. Methods: A total of 182 patients older than 18 years with non-valvular AF and being treated with OACs for at least 6 months according to current AF guidelines who were admitted to outpatient clinics between July 2014 and January 2015 were included in this cross-sectional study. The exclusion criteria were receiving OACs for conditions other than non-valvular AF and being unable to answer the questionnaire. A questionnaire was administered to all participants to evaluate HRQoL, depression and anxiety. The mean differences between the groups were compared using Student's t-test; the Mann-Whitney U test was applied for comparisons of the medians. Results: The annual number of hospital admissions was significantly higher in the warfarin group (p<0.001), and all HRQoL scores were significantly lower and Hospital Anxiety and Depression Scale (HADS) score was higher in the warfarin group (p<0.001). History of any type of bleeding was significantly higher in the warfarin group (p<0.001). However, none of the patients had major bleeding. Among patients who experienced bleeding, all HRQoL scores were significantly lower and HADS score was significantly higher (p<0.001 and p=0.002, respectively). Conclusion: Warfarin-treated patients had higher levels of self-reported symptoms of depression and anxiety and compromised HRQoL when compared with NOAC-treated patients. The results may be explained by higher rates of bleeding episodes and higher number of hospital admissions, which may cause restrictions in life while on warfarin treatment.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 50 条
  • [31] Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation
    Halperin, Jonathan L.
    Dorian, Paul
    CURRENT CARDIOLOGY REVIEWS, 2014, 10 (04) : 297 - 302
  • [32] Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation
    Dilokthornsakul, Piyameth
    Nathisuwan, Surakit
    Krittayaphong, Rungroj
    Chutinet, Aurauma
    Permsuwan, Unchalee
    HEART LUNG AND CIRCULATION, 2020, 29 (03) : 390 - 400
  • [33] Factors associated with low health-related quality of life among younger and older Thai patients with non-valvular atrial fibrillation
    Varalak Srinonprasert
    Kasem Ratanasumawong
    Tomon Thongsri
    Somchai Dutsadeevettakul
    Pongpun Jittham
    Weerapan Wiwatworapan
    Rungroj Krittayaphong
    Quality of Life Research, 2019, 28 : 2091 - 2098
  • [34] Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naive non-valvular atrial fibrillation patients in the US Department of defense population
    Gupta, Kiran
    Trocio, Jeffrey
    Keshishian, Allison
    Zhang, Qisu
    Dina, Oluwaseyi
    Mardekian, Jack
    Nadkarni, Anagha
    Shank, Thomas C.
    BMC CARDIOVASCULAR DISORDERS, 2019, 19 (1)
  • [35] Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
    Laliberte, Francois
    Pilon, Dominic
    Raut, Monika K.
    Nelson, Winnie W.
    Olson, William H.
    Germain, Guillaume
    Schein, Jeff R.
    Lefebvre, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (08) : 1521 - 1528
  • [36] A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry
    Asuncion Esteve-Pastor, Maria
    Miguel Rivera-Caravaca, Jose
    Ruiz-Ortiz, Martin
    Muniz, Javier
    Roldan-Rabadan, Inmaculada
    Otero, Deborah
    Lopez-Galvez, Raquel
    Cequier, Angel
    Bertomeu-Martinez, Vicente
    Badimon, Lina
    Anguita, Manuel
    Lip, Gregory Y. H.
    Marin, Francisco
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (12) : 1457 - 1465
  • [37] Comparison of the Efficacy and Safety of Apixaban and Warfarin in the Prevention of Stroke in Patients With Non-valvular Atrial Fibrillation: A Meta-Analysis
    Memon, Rahat A.
    Hamdani, Syed Shah Qasim
    Usama, Ali
    Aisha, F. N. U.
    Kundi, Hayan
    Mathavan, Mohit
    Khalid, Malaika
    Khan, Areeba
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [38] Differences in safety and efficacy of oral anticoagulants in patients with non-valvular atrial fibrillation: A Bayesian analysis
    Sun, Zhe
    Liu, Yuqi
    Zhang, Ye
    Guo, Xinhong
    Xu, Yong
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2019, 73 (04)
  • [39] Cost-Effectiveness of Apixaban Compared to Other New Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation
    Rudakova, A. V.
    Tatarskiy, B. A.
    KARDIOLOGIYA, 2014, 54 (07) : 43 - 52
  • [40] Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients' characteristics and out-of-pocket payments
    Al-Obaidi, Siraj
    Hijazeen, Rima
    Arabyat, Rasha M.
    Alabbadi, Ibrahim
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (07) : 845 - 852